

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Symptom Management & Survivorship
Committee

Symptom Management & Survivorship Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Thursday, October 8, 2026 4:30 p.m. - 6:30 p.m.
 Room: Regency A (Ballroom Level)

Agenda

Overview Topics: Drs. Fisch and Henry

Patient Advocate Update: Lee Jones

BIQSFP Study Discussion:

"Pre-treatment Vitamin D Insufficiency to Predict Efficacy of Cryocompression for Prevention of Taxane-induced Peripheral Neuropathy" associated with "SWOG S2205 ICE-COMPRESS" - Dr. Daniel Hertz

Updates on Concepts in Development

"Impact of Intravenous Iron on Symptoms in Patients Receiving Adjuvant Systemic Anticancer Therapy for Colorectal Cancer." - Dr. Jamie Mills

Updates on Active Trials

Brainstorming Session - Building on the Working Group Ideas and Fostering Further Ideas for New Interventional SMS Study Concepts

Concepts in Development

SXXXX, "Vitamin D for Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Meghna Trivedi and Daniel Hertz.

SXXXX, "Lowering ANC Thresholds for Duffy Null Patients with Breast Cancer Receiving CDK 4/6 Inhibitor Therapy." Study Chair: Dr. Lauren E. Merz

SXXXX, "RECOG: Relugolix vs. GnRH agonist: Evaluation of COGNITIVE outcomes in prostate cancer." Study Chairs: Drs. Clara Hwang and Laura Graham

S2435, "App-Supported Sleep Coaching for Cancer Survivors and Their Bedroom Partners." Study Chair: Dr. Rina S. Fox.

SXXXX, "Impact of Intravenous Iron on Symptoms in Patients Receiving Adjuvant Systemic Anticancer Therapy for Colorectal Cancer" Study Chair: Dr. Jamie Mills

Active Studies

S2013, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective

Observational Study." Study Chairs: Drs. Krishna S. Gunturu and Dawn L. Hershman. Activated: 8/16/21.

S2205, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Melissa K. Accordino and Katheryn Pennington. Activated: 3/16/23.

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Study Chairs: Drs. Jill Hamilton-Reeves and Jeffrey M. Holzbeierlein. Activated: 02/21/19; Permanently closed: 10/20/23.

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Study Chairs: Drs. Jessica Hwang, Anna S. Lok, Adam Gehring, and Jordan Feld. Activation: 02/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Study Chairs: Drs. Meghna S. Trivedi, Dawn L. Hershman, and Thomas H. Brannagan. Activated: 03/01/19; Permanently closed: 11/15/21.

S2010, "A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Study Chairs: Drs. N. Lynn Henry and Dawn L. Hershman. Activated: 1/17/23; Permanently closed: 1/15/25.

Other SWOG Studies with Symptom Control and QOL Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Study Chairs: Drs. Reshma Jags, Pavani Chalasani, Jean Moran, and Corey Speers. Activated: 09/12/18; Permanently closed: 07/01/24.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Strmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Study Chairs: Drs. Melissa K. Accordino, Dawn Hershman, and Scott D. Ramsey. Activated: 7/16/18.

Symptom Management & Survivorship Committee

S1904, "Cluster Randomized Controlled Trial of Patient and Provider

Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Study Chairs: Drs. Katherine D. Crew, Rita Kukafka, Dawn L. Hershman, Parijatham Thomas, and Allison Caban-Holt. Activated: 9/1/20; Permanently closed: 6/14/24.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial

Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Study Chairs: Drs. Veena Shankaran, Ruth Carlos, Dawn L. Hershman, Shelby Langer, and Scott D. Ramsey. Activated: 7/26/21; Permanently closed: 12/16/24.

S2108CD, "A Cluster Randomized Trial Comparing an Educationally

Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy." Study Chairs: Drs. Jens Rueter, Meghna S. Trivedi, Banu E. Symington, Paul Tseng, and Dawn L. Hershman. Activated: 8/22/22; Permanently closed: 11/22/24.

GU

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST)

Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Study Chairs: Drs. Brian F. Chapin, Ana Aparicio, and Richard Valicent. Activated: 9/17/18.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with

or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." SWOG Study Chair: Drs. Parminder Singh, Seth P. Lerner, and Sameer Jhavar. Activated: 04/19/18; Permanently closed: 04/01/24.

GI

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and

Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Study Chairs: Drs. Jason A. Zell, Lance, and Powel H. Brown. Activated: 3/1/13; Permanently closed: 6/30/23.

Leukemia

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax

and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Study Chairs: Drs. Deborah Stephens, Brian Hill, and Maziar Shadman. Activated: 12/14/20.

Lung

S1914, "A Randomized Phase III Trial of Induction/Consolidation

Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Study Chairs: Drs. Megan E. Daly, Charles B. Simone, II, Karen Kelly, and Jeffrey D. Bradley. Activated: 3/25/20.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and

Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Study Chairs: Drs. Chad Rusthoven, Paul Brown, Jeffrey S. Wefel, Abhijit Patel, and N. Lynn Henry. Activated: 1/10/20; Permanently closed: 12/15/25.

Lymphoma

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or

Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age $\geq$ 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Study Chairs: Drs. Alex F. Herrera and Jonathan Friedberg. Activated: 7/19/19; Permanently closed: 12/1/22.

S1918, "A Phase II/III Randomized Study of R-miniCHOP with or without

Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Study Chairs: Drs. Elizabeth Brem and Sonali Smith. Activated: 3/19/21; Temporarily closed: 4/1/25.

Myeloma

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) +

Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Study chairs: Drs. Amrita Krishnan, Saurabh Chhabra, and Natalie S. Callander. Activated: 6/27/19; Step 1 Closed to accrual: 1/15/25.

NCCTN Studies

CTSU/NRG-GI004, "Colorectal Cancer Metastatic dMMR Immunotherapy

(COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Caio Max Sao Pedro Rocha Lima and Michael Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21; Permanently closed: 9/2/25.

Symptom Management & Survivorship Committee

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

NRG-GI004/S1610 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. Lima CMSPR, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil MF, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. *Journal of Clinical Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42525921/>

A221504 Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. Gupta P, Gupta K, Dockter T, Harlos E, Chow S, Subbiah N, Ruddy K, Bazhenova L, Terstriep S, Huang C, Kratzke R, Vokes E, Loprinzi C. *Cancers*. 2026. <https://pubmed.ncbi.nlm.nih.gov/41681846/>

S1600 Flow cytometry method to identify arginase-1 expressing MDSCs. Srinivasan P, Bechtel M, Wyczzechowska D, Ochoa A, Fisch M, Henry NL, Unger JM, Hamilton-Reeves J. *MethodsX*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42233054/>

S1600 Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial. Hamilton-Reeves JM, Unger JM, Holzbeierlein JM, Lew DL, Ryan MJ, Daneshmand S, Lerner SP, Kukreja JEB, Lee E, Tabayoyong WB, Hershman DL, Fisch MJ, Henry NL. *JAMA Network Open*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42475098/>

S1706 Acute Toxicity in SWOG 1706, a Randomized Trial Comparing Radiotherapy with and without Concurrent Olaparib for Inflammatory Breast Cancer. Jaggi R, Meisner A, Chalasani P, Barlow WE, Bellon JR, Henry NL, Lew D, Matuszak MM, Moran JM, Pierce LJ, Rakovitch E, Reyes SJ, Speers C, Unger JM, White JR, Woodward WA, Zellars RC, Pusztai L, Sharma P. *Journal of Radiation Oncology*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42520859/>

S1714 Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714. Trivedi M, Unger J, Henry NL, Darke A, Hertz D, Brannagan T, Reyes S, Schneider B, Irvin W, Hathaway A, Vander Woude A, Gudena V, Cabrera-Galeana P, Orsted M, LeBlanc M, Fisch M, Hershman D. *JAMA Network Open*. 2026.

<https://pubmed.ncbi.nlm.nih.gov/41961500/>

Multiple Studies Comparison of five definitions of meaningful change on patient-reported outcomes in four SWOG clinical trials. Jones SMW, Till C, Unger JM, Hershman DL, Henry NL, Berry DL, Patel S, Hall E. *Journal of Patient Reported Outcomes*. 2026. <https://doi.org/10.1186/s41687-026-01182-2>. In press.

S1105 The impact of intervention-induced symptom awareness on patient reported outcomes in a randomized mobile health intervention for medication adherence in cancer care. Hershman DL, Till C, Jones S, Fisch M, Henry NL, Unger JM. *Advances in Patient-Reported Outcomes*. 2026. <https://doi.org/10.1016/j.apro.2026.100344>

Submitted Manuscripts

S1714 Vitamin D Insufficiency and Risk of Taxane-Induced Peripheral Neuropathy: Results from SWOG S1714. Nguyen-Hoang N, Unger JM, Darke A, Fisch MJ, Henry NL, Hershman DL, Trivedi MS, Hertz DL. Submitted 2026.

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202
Audie L Murphy VA Hospital	-	26	-	-	-	-	-
Baptist Memorial Health Care/Mid South NCORP Consortium	-	8	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	1	-	-	-	-
Cancer Research for the Ozarks NCORP	-	12	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	190	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	21	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
Columbia University NCI Community Oncology Research Program	25	58	44	-	1	-	-
Columbus NCI Community Oncology Research Program	-	37	-	-	-	-	-
CommonSpirit Health Research Institute	13	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-
Georgia CaRes	-	40	-	-	-	-	-
Georgia NCI Community Oncology Research Program	20	78	-	3	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	9	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	4	-	-	-	-	-	-
Heartland Cancer Research NCORP	25	287	-	-	-	-	-
Henry Ford Hospital	-	29	5	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	27	13	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	24	-	-	-	-	-	-
Intermountain Medical Center	-	3	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	28	89	-	-	-	-	-
Lahey Clinic	12	63	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	63	-	-	-	-	-
Mercy Medical Center - Des Moines	-	9	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	20	29	-	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	7	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	1	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	8	-	-	-	-	39
Nevada Cancer Research Foundation NCORP	-	-	-	-	3	-	4
Northwestern University LAPS	7	-	-	-	-	-	-
Oregon Health and Science University	-	12	-	-	-	2	-
Our Lady of the Lake Hospital	-	25	-	-	-	-	-

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202
Pacific Cancer Research Consortium NCORP	11	6	-	-	-	-	-
Regents of the University of Michigan	31	-	-	-	-	-	-
Rhode Island Hospital	-	-	25	-	-	-	-
STCC at DHR Health Institute for Research and Development	18	55	42	8	-	-	-
Salem Hospital	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	2	204	102	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	8	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	10	4	-	-	1	-	-
The Hawaii NCORP	9	11	53	-	-	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	21	-	30	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	18	94	22	1	-	3	-
Tufts Medical Center	-	-	-	-	-	-	4
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	6	-	-	-	-	-
UC San Diego Moores Cancer Center	2	2	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	5	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	4	22	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	8	-	-	-	-
University of Arizona LAPS	-	5	-	-	-	-	-
University of Arkansas for Medical Sciences	6	25	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	7	13	-	-	-	-	-
University of Colorado Cancer Center LAPS	3	38	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	17	53	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	3	-	6	2	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	29	-	-	-	-
Western States Cancer Research NCORP	-	1	4	-	-	-	-
Wisconsin NCI Community Oncology Research Program	8	37	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	-	-	-	-
ALLIANCE	42	385	94	-	-	-	-
ECOG-ACRIN	37	140	15	-	-	-	-
NRG	87	311	153	-	-	-	-
Total	565	2,543	633	18	7	13	47

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	EAQ211	NRGCC010	NRGCC011	NRGCC014	NRGCC015
Audie L Murphy VA Hospital	-	-	-	-	-
Baptist Memorial Health Care/Mid South NCORP Consortium	-	-	3	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	4
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	3	-	-
Columbia University NCI Community Oncology Research Program	-	-	-	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	1	-	-
Essentia Health NCI Community Oncology Research Program	1	-	-	-	-
Georgia CaRes	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	15	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	1
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-
Lahey Clinic	-	-	4	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-
Mount Sinai Hospital	-	-	2	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-
Our Lady of the Lake Hospital	-	-	-	-	-

Symptom Management and Survivorship

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	EAQ211	NRGCC010	NRGCC011	NRGCC014	NRGCC015
Pacific Cancer Research Consortium NCORP	-	-	-	-	-
Regents of the University of Michigan	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-
Salem Hospital	-	-	14	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-
Stanford Cancer Institute Palo Alto	4	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	16	-
The Don and Sybil Harrington Cancer Center	-	-	3	-	4
The Hawaii NCORP	-	-	-	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	2	-	12	1	-
Tufts Medical Center	-	-	-	-	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-
University of Arizona LAPS	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	-	-	2	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	4	-	-
University of Mississippi Medical Center	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	2	-	-	-
University of Rochester LAPS	12	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	-	5	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-
ALLIANCE	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-
NRG	-	-	-	-	-
Total	19	17	48	22	10

